Unknown PHASE1 INTERVENTIONAL 2-arm NCT03468751

Phase 1 Study of HLX10, a Monoclonal Antibody Targeting Programmed Death-1 (PD-1) in Patients With Advanced Solid Tumors

A Prospective Open-label Dose Escalation Phase 1 Study to Investigate the Safety and Tolerability, and to Determine the Maximum Tolerated Dose and Recommended Phase 2 Dose, of HLX10 in Patients With Advanced Solid Tumors

Sponsor: Henlix, Inc

Conditions Solid Tumor

Interventions HLX10

Updated 8 times since 2018 Last updated: May 28, 2020 Started: Feb 14, 2018 Primary completion: Jun 30, 2020 Completion: Aug 31, 2020

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Solid Tumor, this trial is ongoing. The trial is conducted by Henlix, Inc and has accumulated 8 data snapshots since 2018. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

8 versions recorded

Sep 2025 — Present [monthly]

Unknown PHASE1
Sep 2024 — Sep 2025 [monthly]

Unknown PHASE1
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE1

Status: Unknown Status → Unknown
Oct 2021 — Jul 2024 [monthly]

Unknown Status PHASE1

Status: Recruiting → Unknown Status
Jan 2021 — Oct 2021 [monthly]

Recruiting PHASE1

▶ Show 3 earlier versions

Jul 2020 — Jan 2021 [monthly]

Recruiting PHASE1
Jun 2019 — Jul 2020 [monthly]

Recruiting PHASE1
Apr 2018 — Jun 2019 [monthly]

Recruiting PHASE1

First recorded

Feb 2018

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Henlix, Inc

Data source: Henlix, Inc

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Taipei, Taiwan